News and Events
April | 2021
"Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcionoma of the prostate" by Borkowetz et al. (September 2019) is published in the International Journal of Cancer and demonstrates that immunohistochemical expression of NRP2 is a prognostic marker in prostate cancer. This work is executed in close collaboration with the Department of Urology, University of Dresden Medical Center, Germany.
"Silencing of neuropilins and GIPC1 in pancreatic ductal adenocarcinoma exerts multiple cellular and molecular antitumor effects" by Borchardt et al. (October 2019) is published in Scientific Reports and shows that NRP-2 can be a target for therapy in pancreatic cancer. This work is executed in close collaboration with Achim Aigner of the Rudolf-Boehm-Institute for Pharmacology and Toxicology of the University of Leipzig, Germany.
"Linking NRP2 with EMT and chemoradioresistance in bladder cancer" by Schulz et al. (January 2020) is published in Frontiers in Oncology and demonstrates an important role of NRP2 in bladder cancer progression. This work is executed in close collaboration with the OncoRay, National Center for Radiation Research in Oncology, Dresden, Germany.
"Neuropilin-2 and its transcript variants correlate with clinical outcome in bladder cancer" by Förster et al. (April 2021) is published in "Genes" and demonstrates that NRP2A is an independent prognostic marker in bladder cancer. This work was executed in collaboration with the Department of Urology and Urosurgery, Medical Faculty Mannheim, University of Heidelberg.
In collaboration with the research group of Prof. Kaustubh Datta at the University of Nebraska Medical Center and partners at the Mayo Clinic Foundation as well as at the University of Utah, we have discovered a novel role of osteoclast derived Neuropilin-2 during prostate cancer bone metastases. This study has been accepted in the journal "Bone Research" and will be published online soon.
Together with the Department of Urology of the Medical Faculty Mannheim, University of Heidelberg, we were able to show a prognostic role of NRP2 in a cohort of bladder cancer patients.
Muders lab collaborates with aTyr Pharma, San Diego, CA, USA to develop a tissue based companion diagnostic test for future anti-NRP2 therapies.
Rui-zhi Bao joined our lab for her PhD.
The annual meeting of the Mayo Clinic Alumni will take part in Bonn in 2021.
The Annual Meeting of the German speaking chapter of the Mayo Alumni Association is organized by the Muders lab. It will take place from September 24th to September 26th, 2021.
Detailed program and location will follow.
January | 2020
Muders lab continues its collaboration with Atyr Pharma Inc., San Diego, USA.
Summer | 2018
After moving into the Biomedical Center (BMZ) of the University Hospital in Bonn, our lab is now up and running!
